Health brief
AI Negligence Claims, NICE Rulings, and Health Safety Inquiries
NHS Resolution faces its first AI negligence claims as NICE decisions and public inquiry evidence challenge UK health governance.
Health
NICE rejected Gilead's twice-yearly HIV injection over cost — forcing price negotiations before NHS distribution can proceed.
BackgroundLenacapavir provides 6-month HIV protection via injection, offering an effective alternative to daily oral pills for high-risk populations. NICE evaluates drug treatments against a cost threshold of £20,000 to £35,000 per quality-adjusted life year.
- NICE concluded cost-per-QALY estimates significantly exceeded maximum NHS cost-effectiveness thresholds, blocking public funding despite high clinical efficacy across clinical trial data.
- Sexual health advocates and clinical bodies warned the rejection deprives vulnerable patients who struggle with daily oral medication adherence.
- The British Association for Sexual Health urged Gilead and NHS England to reopen commercial pricing negotiations to establish a discounted access agreement.
Health
First AI clinical negligence claims hit the NHS — establishing that doctors remain legally liable for validating AI diagnostic tools.
BackgroundNHS Resolution manages clinical negligence indemnity schemes for NHS trusts across England. Hospitals increasingly deploy AI software for patient triage, radiograph screening, and diagnostic decision support.
- NHS Resolution issued legal guidance confirming clinical care involving AI tools remains covered under existing NHS trust indemnity schemes.
- Guidance emphasized that clinicians remain legally responsible for independently verifying AI diagnostic outputs before treatment, preventing trusts from shifting legal blame onto automated software systems.
- Legal claims will target treating NHS trusts directly rather than software vendors, though trusts retain rights to pursue third-party product liability recovery against software developers.
Health
NICE approved a personalized quadruplet myeloma treatment — introducing minimal residual disease testing to halt unnecessary chemotherapy.
BackgroundMultiple myeloma is an incurable blood cancer affecting bone marrow plasma cells across the UK. Quadruplet therapy combines targeted monoclonal antibodies with chemotherapy to maximize complete disease response rates.
- An estimated 1,900 UK patients annually will gain access to the first-line daratumumab quadruplet combination through routine NHS funding.
- The guidance introduces minimal residual disease testing, allowing patients achieving 12-month negative status to cease maintenance chemotherapy, avoiding prolonged drug toxicity.
- Stopping maintenance treatment reduces hospital visits, lowers adverse drug side effects, and saves NHS oncology services significant expenditure on continuous drug administration.
Health
Public inquiry testimony exposed wrong-site surgeries by surgeon Sam Eljamel — uncovering systemic oversight failures at NHS Tayside.
BackgroundSam Eljamel operated as head of neurosurgery at NHS Tayside until his suspension in 2013 following severe patient complications. A public inquiry was launched to investigate governance failures regarding harm caused to over 200 patients.
- Royal College of Surgeons experts testified that wrong-site operations represent classified 'never events' under NHS clinical safety rules.
- The inquiry heard testimony that Eljamel concealed surgical errors from medical colleagues and altered post-operative patient records to hide complications.
- Inquiry leaders are examining why NHS Tayside executive management failed to intervene despite receiving repeated clinical safety warnings from senior colleagues.
Health
Health
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
